Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
2.720
+1.315 (93.59%)
At close: Jan 30, 2026, 4:00 PM EST
2.750
+0.030 (1.10%)
After-hours: Jan 30, 2026, 7:38 PM EST
Tempest Therapeutics Employees
Tempest Therapeutics had 21 employees as of June 30, 2025. The number of employees decreased by 3 or -12.50% since the number was reported on December 31, 2024.
Employees
21
Change
-3
Growth
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,716,857
Market Cap
13.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 21 | -3 | -12.50% |
| Dec 31, 2024 | 24 | 7 | 41.18% |
| Dec 31, 2023 | 17 | -2 | -10.53% |
| Dec 31, 2022 | 19 | 2 | 11.76% |
| Dec 31, 2021 | 17 | 3 | 21.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| BioLineRx | 28 |
| Applied Therapeutics | 28 |
| BioCardia | 20 |
| Moleculin Biotech | 17 |
| Soligenix | 16 |
| CalciMedica | 15 |
| Cocrystal Pharma | 11 |
TPST News
- 12 days ago - Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - GlobeNewsWire
- 2 months ago - Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 - GlobeNewsWire
- 3 months ago - Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China - GlobeNewsWire
- 8 months ago - Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - GlobeNewsWire